AMP 2018 Committee and Subdivision Annual Reports

Board of Directors

President
President-Elect; Awards and Strategic Opportunities Committees Chair
Past President and Nominating Committee Chair
Secretary-Treasurer and Finance Committee Chair
Clinical Practice Committee Chair
Economic Affairs Committee Chair
International Affairs Committee Chair
Membership Affairs Committee Chair
Professional Relations Committee Chair
Program Committee Chair
Training & Education Committee Chair
Genetics Subdivision Chair
Hematopathology Subdivision Chair
Infectious Diseases Subdivision Chair
Informatics Subdivision Chair
Solid Tumors Subdivision Chair
Executive Director

Kojo S. J. Elenitoba-Johnson, MD
Victoria M. Pratt, PhD
Federico A. Monzon, MD
Daniel E. Sabath, MD, PhD
Antonia R. Sepulveda, MD, PhD
Samuel K. Caughron, MD
Rami Mahfouz, MD, MPH
Ron M. Przygodzki, MD
Jordan Laser, MD
Lynne V. Abruzzo, MD PhD
Paul G. Rothberg, PhD
Cecilia C.S. Yeung, MD
Birgit Funke, PhD
Annette S. Kim, MD, PhD
David R. Hillyard, MD
Alexis B. Carter, MD
Roger D. Klein, MD, JD
Mary Steele Williams, MNA, MT(ASCP)SM, CAE
COMMITTEE MEMBERS:
Chair        Victoria M. Pratt, PhD
Member     Helen Fernandes, PhD
Member     Margaret L. Gulley, MD
Member     David R. Hillyard, MD
Member     Ted E. Schutzbank, PhD

PURPOSE SUMMARY:
The Awards Committee consists of 5 members (4 appointed) who oversee the nomination and selection of the recipient of the Award for Excellence in Molecular Diagnostics, the Jeffrey A. Kant Leadership Award, and, if determined applicable, the recipient(s) of the Meritorious Service Award(s). The Committee evaluates the current awards, addresses the need for new awards, and conducts the formal nomination process for potential award recipients.

The President-Elect serves as the Chair of the Awards Committee. The remaining 4 committee members are appointed by the Board and serve rotating two-year terms. The annual selection of 2 incoming committee members is conducted by the committee and the candidates’ names are brought forward for Board approval and appointment.

Timeline for AMP Awards
The Awards Committee coordinated the timing of the AMP recognition awards as follows:
   November through February: Nominations from the Board, Committees, and Membership
   March: Review and selection by Awards Committee
   April through May: Notification of recipients
   May through September: Assess need for new recognition awards, if any

Award Recipients
- 2018 Jeffrey A. Kant Leadership Award: Roger D. Klein, MD, JD
- 2018 Meritorious Service Award: Kevin C. Halling, MD, PhD
- 2020 Award for Excellence in Molecular Diagnostics: To be announced
COMMITTEE MEMBERS:

Chair
Antonia R. Sepulveda, MD PhD

Genetics Subdivision Representative
Jess F. Peterson, MD

Genetics Subdivision Representative
Josh Deignan, PhD

Hematopathology Subdivision Representative
Keyur P. Patel, MD PhD

Hematopathology Subdivision Representative
Noah A. Brown, MD

Infectious Diseases Subdivision Representative
Susan Butler-Wu, PhD

Infectious Diseases Subdivision Representative
Kenneth L. Muldrew, MD

Informatics Subdivision Representative
Mark Boguski, MD PhD

Informatics Subdivision Representative
Justin Zook, PhD

Solid Tumors Subdivision Representative
Kandelaria Rumilla, MD

Solid Tumors Subdivision Representative
Pranil Chandra, DO

Junior Member
Alex Greninger, MD PhD

Junior Member
Megan Wachsmann, MD

PURPOSE SUMMARY:
The Clinical Practice Committee (CPC) is comprised of AMP members with expertise in one or more of the molecular specialties: infectious diseases, hematopathology, solid tumors, genetics and informatics. Its purpose is to address the challenges of clinical laboratories and, therefore, improve the service we provide. Separate working groups plan, organize and coordinate efforts such as practice guidelines, sample exchanges, reporting surveys, validation and quality control measures, and advocate for policies that will advance the practice of high quality clinical molecular pathology services.

Publications


- **March 2018**: *Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology*. Led by Neal I. Lindeman with Philip T. Cagle, Dara L. Aisner, Maria E. Arcila, Mary Beth Beasley, Eric H. Bernicker, Carol Colasacco, Sanja Dacic, Fred R. Hirsch, Keith Kerr, David J. Kwiatkowski, Marc Ladanyi, Jan A. Nowak, Lynette Sholl, Robyn Temple-Smolkin,

Clinical Practice Guidelines, Working Groups, and Task Forces


- **In development:** AMP Recommendations for Laboratory Detection and Interpretation of Intragenic (Exonic Level) Deletions/Duplications. Chaired by Madhuri Hegde with Elaine Lyon, Carolyn Sue Richards and Birgit Funke.

- **In development:** Variant Interpretation Test Across Labs (VITAL). Chaired by Elaine Lyon with Madhuri Hegde, Julie Gastier-Foster, Carolyn Sue Richards, Sherri Bale and Glenn Palomaki. Project supported by an unrestricted educational grant from QIAGEN, Inc.

- **In development:** AMP Guidance for Non-standard or Emerging Applications: Liquid Biopsy. Chaired by Christina Lockwood with Laetitia Borsu, Christopher Gocke, Milena Cankovic, Kandelaria Rumilla, Meera Hameed, Jason Merker (CAP representative), Geoffrey Oxnard (ASCO representative), Jacquelyn Reuther and Antonia Sepulveda.

- **In development:** AMP Guidance/Standards for NGS Germline Variant Confirmation. Chaired by Kristy Crooks with Linda Jo Bone Jeng, Avni Santani, Diana Mandelker, Steve Lincoln, Ryan Schmidt and Kelly Hagman (NSGC representative).

- **In development:** AMP NGS utility for assessment of T/B-cell clonality. Chaired by David Viswanatha with Keyur Patel, Maria Arcila, Timothy Greiner, David Wu, Frank Kuo (SH representative), Joseph Khoury and Habibe Kurt.

- **In development:** AMP report on New Frontiers in Infectious Diseases Multiplex Testing. Chaired by Michael Lewinski with Susan Butler-Wu, Kevin Alby, Jennifer Dien Bard, Alex Greninger, Esther Babady (PASCV representative), Duane Newton (ASM representative), Kimberly Hanson (IDSA representative) and Samia Naccache.
• In development: **AMP Guidance/Standards for Tumor Mutational Burden Testing by Molecular Methods.** Chaired by Larissa Furtado with Jeffrey Gregg, Benjamin Kipp, Jonathan Nowak, Susan Hsiao, Antonia Sepulveda, Daniel Dolderer, Jeremy Segal, Lauren Ritterhouse and Ahmet Zehir.

• In development: **AMP report on Implementation of AMP/ASCO/CAP Reporting and Interpretation of Somatic Sequence Variants Recommendations in Clinical Practice.** Chaired by Marilyn Li and Marina Nikiforova with Somak Roy, Cindy Vnencak-Jones and Scott Turner.

• In development: **Appropriate Collection and Handling of Thoracic Specimens for Laboratory Testing.** The College of American Pathologists (CAP) in collaboration with the American College of Chest Physicians (CHEST), Association for Molecular Pathology (AMP), American Society for Cytopathology (ASC), American Thoracic Society (ATS), Pulmonary Pathology Society (PPS), Papanicolaou Society of Cytopathology (PSC), Society of Interventional Radiology (SIR), and Society for Thoracic Radiology (STR). AMP Expert Panelist and Steering Committee member Jan Nowak; AMP Expert Panelist Dara Aisner.

• In development: **Diagnostic Testing for Diffuse Gliomas.** The College of American Pathologists in Collaboration with Association of Neuropathologists (AANP), American Society of Clinical Oncology (ASCO), Association for Molecular Pathology (AMP), Society for Neuro-Oncology (SNO), AMP Expert Panelists Peter Canoll and Dolores Lopez-Terrada.

• In development: **Checkpoint Inhibitor Testing in Body Sites Other Than Lung.** The College of American Pathologists in Collaboration with the American Society of Clinical Oncology (ASCO) and Association for Molecular Pathology (AMP). AMP Expert Panelist Antonia Sepulveda.

**Representatives to Other Organizations**

- CAP Molecular Oncology Committee, Daniel Farkas
- ACMG Interpretation of Sequence Variants Update workgroup, Scott Turner
- NIST Genome in a Bottle Steering Committee, Monica Basehore
- ACMG Incidental Findings in Inherited Diseases Update Workgroup, Carolyn Sue Richards
- CAP/AMP/ASCO Roundtable, Marina Nikiforova
- ACMG ClinGen Somatic Cancer Clinical Domain Workgroup, Marilyn Li
- CAP/ASCP /ASCO HER2 Testing in Gastroesophageal Adenocarcinoma Guideline project, Advisory Panelist, William Sukov
- ASCO-CAP Liquid Biopsies White paper project, Christina Lockwood
- CAP NGS Test Validation/Metrics manuscripts Working group, Marina Nikiforova
- FNIH Biomarkers Consortium Steering Committee for Inflammation and Immunity, Maria Bettinotti
- FNIH Biomarkers Consortium Steering Committee for Metabolic Diseases, Ming Rong
- FNIH Biomarkers Consortium Steering Committee for Cancer, Snehal Patel
- American Society of Cytopathology, Sinchita Roy-Chowdhuri
- American Society for Microbiology (ASM) Next Generation Sequencing Coalition, Benjamin Pinsky
- CAP Personalized Healthcare Committee Incidental Findings in the Context of Tumor Genomic Evaluations Project Workgroup, Pranil Chandra
• CAP Cytopathology Committee/Personalized Healthcare Committee Pre-analytics for Precision Medicine Cytology Preparations for Molecular Testing Project Team, Nikoletta Sidiropoulos and Jane Gibson
• Medical Device Innovation Consortium (MDIC) Somatic Reference Samples working group, Feras Hantash
• CAP Genomic Medicine Resource Committee, Ryan Schmidt
• Clinical Laboratory Standards Institute (CLSI) Nucleic Acid Sequencing Methods in Diagnostic Laboratory Medicine, 2nd Edition (MM09) Working Group, Avni Santani

Additional Accomplishments
• AMP hosted a Reference Materials Forum prior to the 2018 Annual Meeting on Tuesday, October 30, 2018 with representatives from CDC, NIST, and NCI.
• Multiple CPC and Scientific Subdivision members hosting or presenting in AMP Webinar events.
• CPC members actively brainstormed and launched five new projects in 2018. Several additional project ideas are awaiting to be launched in the near future.
• The AMP Test Directory continues to be populated with additional labs and tests.
• Multiple early career AMP members working on CPC working groups as Junior members.

Congratulations on a job well done!

Requests from the CPC:
• We encourage all AMP members to alert the Board or appropriate committees when laboratory guidelines or recommendations are opened for public comment.
• We encourage AMP members to actively contribute to calls for information from the CPC.
• Suggestions from AMP members for new CPC initiatives are always welcome! Visit http://amp.org/committees/clinical_practice/ for more details.
COMMITTEE MEMBERS:

Chair: Samuel K. Caughron, MD
Vice Chair, New Codes & Pricing: Anthony N. Sireci, MD, MS
Vice Chair, Coverage: Pranil Chandra, DO
Member: Dara L. Aisner, MD, PhD
Member: Aaron D. Bossler, MD, PhD
Member (Ex Officio – President): Kojo Elenitoba-Johnson, MD
Member: Andrea Ferreira-Gonzalez, PhD
Member: Stephanie Hallam, PhD
Member: Mathew Hiemenz, MD
Member: Lloyd Hutchinson, PhD
Member: Loren Joseph, MD
Member (Ex Officio – PRC Chair): Jordan Laser, MD
Member: Elaine Lyon, PhD
Member: Jay L. Patel, MD
Member (Ex Officio – President-Elect): Victoria Pratt, PhD
Member: Richard Press, MD, PhD
Member: Aparna Rajadhyaksha, MD
Member: Ester Stein, MBA
Member: Katherine Tynan, PhD
Junior Member: Oana C. Rosca, MD
Committee Advisor: Jan A. Nowak, MD, PhD

PURPOSE SUMMARY:

The Economic Affairs Committee (EAC) addresses, advises, and educates the AMP Board of Directors, membership, payors, legislators, and the public on economic issues of importance to the field of molecular pathology; prepares documents of importance to the Centers for Medicare & Medicaid Services (CMS); and develops and advocates for sound economic policies that promote the availability to patients of high quality molecular pathology services. The Committee's scope encompasses short and long-term issues associated with the coding for molecular procedures, utilization of and coverage for molecular pathology, the determination of test pricing, and the potential economic impact of public policy decisions on molecular pathology practice. The Committee interacts with the American Medical Association and other interested organizations in order to achieve common goals.

2018 ACTIVITIES:

CMS, who has oversight of Medicare, has increasingly either denied coverage or reduced payment for many medically necessary molecular pathology tests. The increasing restrictions create a challenging environment for clinical practice and for innovators to translate new genomic discoveries into clinical applications. AMP continues to work with the broader professional community to address policy challenges and opportunities, and engage and inform payors aiming to achieve rightful reimbursements for appropriate patient care services.

National Coverage Determination for NGS for Advanced Cancer for Medicare Beneficiaries

In late November 2017, CMS released a proposed National Coverage Determination (NCD) for next generation sequencing (NGS) for advanced cancer. The proposed policy had the potential to restrict laboratories' ability to obtain Medicare coverage for NGS-based tests for oncology. After working with stakeholders to receive a comment period deadline extension, the EAC worked diligently to assess the content of the NCD and develop a comprehensive response. Additionally, EAC educated AMP members, relevant stakeholders, and organizations.
on this policy and urged them to comment. CMS received over 315 comments, with the majority of the comments expressing concern and seeking clarification from CMS on the proposed policy.

The final policy released by CMS in March was significantly different than the proposed policy. The coverage indications for patients and the laboratories performing NGS based tests were expanded to include more patients; and, patients may now receive an NGS test more than once when certain conditions are met. Coverage for NGS-based tests were expanded to include FDA cleared and approved tests, rather than only FDA approved, with a companion diagnostic indication. Moreover, the coverage with evidence development and non-coverage portions of the proposed policy were removed. A new section was added that allows Medicare Administrative Contractors (MACs) to determine coverage of other NGS-based tests for cancer when the test is performed in a CLIA-certified laboratory. The EAC continues to monitor implementation of this policy to ensure that patient access to NGS tests continues and that MACs continue to develop LCDs for appropriate NGS testing for advanced cancer patients.

Protecting Access to Medicare Act (PAMA)
Under the Protecting Access to Medicare Act (PAMA), laboratories are required to report HCPCS laboratory codes, associated private payor rates, and volume data if they have more than $12,500 in Medicare revenues from laboratory services on the Clinical Laboratory Fee Schedule (CLFS) and receive more than 50% of their Medicare revenues from laboratory and physician services during a collection period. Additionally, under PAMA, CMS is required to establish a coding system for laboratories or manufacturers that want to specifically identify their test (such as Clinical Diagnostic Laboratory Tests or Advanced Diagnostic Laboratory Tests). To fulfill this requirement, AMA generated the Proprietary Laboratory Assay (PLA) codes. In 2018, this new set of codes continues to undergo incorporation into the CMS pricing exercise and Medicare coverage policies. The PLA codes have experienced some hurdles during these processes, which has led to a handful of unexpected problems. To assist laboratories with their PLA codes, AMP is working with both CMS and AMA to help address these problems and to propose solutions moving forward.

Established by PAMA, the Advisory Panel on Clinical Diagnostic Tests (The Panel) advises CMS on various issues under PAMA including payment rates for new tests, including whether to use the “crosswalk” or “gapfill” methodology for initial price determination; application of market rates for established tests; and evaluation and designation of tests as “advanced laboratory diagnostic tests” as defined by the Act. Several AMP members are members of The Panel, with Drs. Aaron Bossler and Pranil Chandra nominated by AMP to serve.

In 2018, a joint EAC and PRC task force of volunteers was convened to monitor the effect of PAMA on clinical laboratories and to continue to develop AMP policy recommendations and possible solutions. CMS solicited stakeholder feedback in an attempt to better understand applicable laboratories’ experiences during the first reporting period under PAMA, including the data reporting, data collection, and other compliance requirements. In our comments to the agency, AMP welcomed the opportunity to work with the agency to ensure that PAMA is implemented successfully and accurately represents the market rates paid for laboratory tests. However, AMP expressed to CMS significant concerns about the process used and rates set from the first reporting period, which have resulted in inaccurate, inequitable and, in some instances, frankly absurd pricing, and encouraged CMS to revisit the reporting requirements and process, as well as address data integrity concerns. Additionally, AMP continues to discuss solution options with other professional organizations.

Clinical Lab Fee Schedule for Calendar Year 2019
During the summer, AMP provided written and oral comments to CMS on the Calendar Year 2019 Clinical Lab Fee Schedule (CY2019 CLFS). Dr. Anthony Sireci represented AMP at the annual CLFS meeting at CMS on June 25, 2018. He presented crosswalk recommendations for the new 2019 CLFS molecular pathology procedures, genomic sequencing procedures (GSPs), and microbiology procedures. There were over 45 molecular procedures on which AMP provided crosswalk recommendations.
In June 2018, CMS released CY2019 Preliminary Gapfill Determinations for a number of codes. AMP expressed concern that the preliminary national limitation amounts (NLAs) did not accurately reflect the value of these procedures. AMP provided information to CMS on the work and resources to perform these procedures and urged CMS to seriously consider the comments provided by AMP and other stakeholders during the preliminary determination comment period as undervaluation of these services threatens patient access to care.

In late September, CMS released the CY2019 CLFS Preliminary Determinations for the new and reconsidered services. AMP appreciates that many of the preliminary CMS determinations align with AMP and other laboratory organizations’ recommendations. However, we are concerned that some of the preliminary recommendations provided by CMS differ vastly from both Advisory Panel recommendations and stakeholder input and, in many cases, do not represent the best options for crosswalks. AMP provided detailed comments to CMS on the preliminary determinations in mid-October. Pricing determinations will be finalized in later this year.

**Educational Initiatives**

Healthcare economics is a complex ecosystem comprised of players in the provider space (doctors, patients, professional societies), healthcare leaders, government agencies and payors in the private sector. Navigating this space can be very difficult but is vital for molecular professionals, particularly laboratory directors, to understand. In 2017, a workgroup formed within the EAC, led by Drs. Dara Aisner and Anthony Sireci, to develop a manuscript that builds off of previous efforts by the EAC to educate others on molecular diagnostic coding, coverage, and reimbursement process, procedures, and policies. We anticipate that the manuscript will be submitted for publication by the end of 2018.

Additionally, the EAC New Codes Committee held a live webinar that explained the history of CPT® coding, how to apply for either a CPT® or a PLA code and the role of AMP in this process. The webinar, titled “the ABCs of CPT® Coding,” was moderated by Training and Education Chair, Dr. Cecilia Yeung, and presented by three EAC members, Drs. Aaron Bossler, Victoria Pratt, and Anthony Sireci. The webinar was very well attended. A written tutorial based on the information provided during the webinar is available in the Advocacy section of AMP’s website. In addition, the webinar is available at educate.amp.org.

**Medicare Administrative Contractors’ (MACs) Local Coverage Determinations (LCDs)**

AMP continues to advocate with CMS regarding coverage policy actions taken by Medicare Administrative Contractors (MACs). Thus far in 2018, AMP has provided responses to various MACs for over 15 draft local coverage determinations (LCDs). Many of the coverage policies released contained substantial problems, either denying or narrowing coverage for important molecular pathology procedures. Currently, AMP is in the process of drafting comments to additional draft LCDs which will be submitted to the MACs in late November. Monitoring emerging policies continued to be a major focus of the committee and was led by Dr. Pranil Chandra. AMP and the College of American Pathologists (CAP) collaborated to draft joint responses. The EAC is very thankful to the AMP members who volunteered their time and subject matter expertise to assist in responding to the diverse coverage policy issues.

**Capitol Hill and Agency Activity**

Throughout 2018, AMP met with numerous offices on Capitol Hill regarding concerns about Medicare coverage and pricing, including majority and minority staff of Senate Finance and House Ways and Means Committees. Additionally, AMP met with CMS representatives from both the pricing and coverage groups about concerns regarding the national coverage determination on NGS, pricing process for PLA codes, and gapfill pricing transparency.

**CPT Codes**

The EAC New Codes and Pricing Subcommittee, led by Dr. Anthony Sireci, advises and reviews new CPT code applications submitted to the Pathology Coding Caucus (PCC) and the Molecular Pathology Advisory Group (MPAG). Throughout the year, the Subcommittee also submits new CPT code change proposals to AMA. In 2018, AMP submitted one CPT code change application. The subcommittee also provided input to CMS’ National
Correct Coding Initiative (NCCI) to help ensure national correct coding methodologies of procedure to procedure (PTP) and medically unlikely edits (MUEs) for molecular procedures.

Outside Organization Involvement

- **Dr. Jan Nowak** serves on the CPT Editorial Panel
- **Drs. Victoria Pratt, Jan Nowak, Aaron Bossler** serve on the AMA Proprietary Laboratory Analyses Technical Advisory Group (PLA-TAG)
- **Dr. Aaron Bossler** serves on the PCC, with **Dr. Anthony Sireci** serving as the technical advisor.
- The AMA Molecular Pathology Advisory Group (MPAG) includes AMP members **Drs. Aaron Bossler, Roger Klein, Elaine Lyon**, and **Victoria Pratt**.
The Finance Committee oversees AMP’s financial affairs, including reviewing quarterly revenue & expense reports and recommending to the Board for approval an annual operating budget and the investment policy for the Association’s assets.
COMMITTEE MEMBERS:

Chair and Membership Affairs Liaison (Middle East)    Rami Mahfouz, MD
Member (Africa)                                       Adewunmi Oluseye Adeoye, MD
Member and Professional Relations Liaison (Europe)   David E. Barton, PhD
Member (East Asia)                                   Yoon-La Choi, MD, PhD
Member (Latin America)                               Renata A. Coudry, MD, PhD
Member and India Affiliate Liaison (South Asia)      Bibhu R. Das, PhD
Member (Australia)                                   Andrew P. Fellowes, PhD
Member and Korea Affiliate Liaison (East Asia)       Chang-Ho Jeon, MD, PhD
Member (Southeast Asia)                               Lynette Lin Ean Oon, MD
Member and Training & Educ Liaison (Latin America)   Roberta Sitnik, PhD
Member and Hong Kong Affiliate Liaison (East Asia)   Lei Po (Chris) Wong, PhD
Member (Africa)                                       Denis Francis York, PhD
German Affiliate Coordinator                         Silke Lassman, PhD
Italy Affiliate Coordinator                           Massimiliano (Max) M. Corsi Romanelli, MD, PhD
Advisor                                               Helen Fernandes, PhD
Advisor                                               Jin-Yeong Han, MD, PhD

PURPOSE SUMMARY:
The International Affairs Committee (IAC):

- Enhances AMP as an international organization
- Promotes AMP’s vision and mission internationally
- Facilitates international presence and participation in AMP groups and programs
- Expands excellence in education and advocacy on behalf of patients, clinicians, and lab professionals to an international audience
- Enables the interaction of scientists and molecular pathologists in the various parts of the world

2018 ACTIVITIES:

- AMP Europe 2018 meeting was held on April 30- May 2, 2018 in Rotterdam, The Netherlands
- AMP 2018 Annual Meeting Events:
  - Molecular Tumor Boards luncheon
- Selected International Trainee Travel Awardees from Brazil, Germany and India.
- Awarded International Membership Grants to 4 scientists from India.
- Welcomed first Institutional Affiliate member, the American University of Beirut Medical Center.
- AMP speakers supported at international (non-U.S.) conferences:
  - Jacqueline Payton, MD, PhD at the 2018 Annual Meeting of Korean Society for Genetic Diagnostics, Seoul, Korea. Organizing Committee AMP Member: Chang-Ho Jeon, MD, PhD.
  - Charles Hill, MD and Laura Tafe, MD at the International Academy of Pathology, Arab Division, XXXII Congress, Dead Sea, Jordan. Organizing Committee AMP Member: Rami Mahfouz
- Created an “Establishing a Molecular Laboratory – Best Practices Around the Globe” Pocket Card. Will be debuted at the AMP Global 2019 in Hong Kong.
AMP Membership Affairs Committee Report, 2018

COMMITTEE MEMBERS:

Chair        Ron M. Przygodzki, MD
Member       Betsy A. Bove, PhD
Member       Yi Ding, MD, PhD
Member       Midhat S. Farooqi, MD, PhD
Member       Katherine Geiersbach, MD
Member       Lisa M. Haley, MS
Member       Giovanni Insuasti-Beltran, MD
Member       Cynthia L. Jackson, PhD
Member       Wanda Reygaert, PhD
Member       Angshumoy Roy, MD, PhD
Member       Yaolin Zhou, MD
International Affairs Liaison     Rami Mahfouz, MD

PURPOSE SUMMARY:

The AMP Membership Affairs Committee (MAC) provides recommendations to Board and assistance to other committees regarding matters of membership and professional development. The committee plays an important role in helping AMP respond to the needs of its members and in facilitating the development of leaders in the field of molecular pathology.

Responsibilities

• Assesses and makes recommendations that will enhance the professional development of AMP members and the benefits of AMP membership
• Provides regular and timely notification to members about opportunities for special projects within or outside of standing committees and subdivisions
• Facilitates leadership development for AMP through various initiatives such as the ad hoc and junior member volunteer process
• Receives requests from Chairs or Board for ad hoc members to work on projects and manages the volunteer application process
• Surveys member volunteers annually regarding their volunteer service experiences
• Surveys the membership periodically regarding how well their membership in AMP is meeting their needs and how well AMP is serving the needs of the profession
• Conducts a member recruitment and retention program

2018 ACTIVITIES:

• Disseminated and assessed responses to the biennial Member Satisfaction Survey
• Selected the winners of the Technologist Travel Awards and Diversity Assistance Grant for 2018
• Planned and hosted the brand new Speed Networking Events at the 2018 Annual Meeting & Expo
• Planned and hosted the New Member & First Timer Lunch at the 2018 Annual Meeting & Expo
• Shepherded the largest growth in membership in the last 5 years
COMMITTEE MEMBERS:

Chair                              Federico A. Monzon, MD
Genetics Subdivision Representative Carolyn Sue Richards, PhD
Genetics Subdivision Representative Bert Gold, PhD
Hematopathology Subdivision Representative Rachel L. Sargent, MD
Hematopathology Subdivision Representative David Viswanatha, MD
Infectious Diseases Subdivision Representative Jim Dunn, PhD
Infectious Diseases Subdivision Representative Amanda Harrington, PhD
Informatics Subdivision Representative Brian Hanson Shirts, MD, PhD
Informatics Subdivision Representative Carlos J. Suarez, MD
Solid Tumors Subdivision Representative John Thorson, MD, PhD
Solid Tumors Subdivision Representative Shelby Melton, MD
President                          Kojo S. J. Elenitoba-Johnson, MD
Executive Director                 Mary Steele Williams, MNA, MT(ASCP)SM, CAE

PURPOSE SUMMARY:

The AMP Nominating Committee is composed of the Past President (Chair) and two representatives from each subdivision. The chair and subdivision representatives are responsible for recruiting qualified AMP members to run for elected offices. A ballot is compiled and made available for voting by all current Regular AMP members. Voting for elected offices takes place during the month of May each year.

2018 ACTIVITIES:

The Nominating Committee nominated Officers and Committee Representatives for the 2018 annual elections.
COMMITTEE MEMBERS:

Chair        Jordan Laser, MD
Member        Linnea M. Baudhuin, PhD
Member (Ex officio – EAC Chair)    Samuel Caughron, MD
Member (Ex officio – President)    Kojo Elenitoba-Johnson, MD
Member        Rajyasree Emmadi, MD
Member        Jill Hagenkord, MD
Member        Robert F. Klees, PhD
Member        Roger Klein, MD, JD
Member        Eric Q. Konnick, MD
Member        Elaine Lyon, PhD
Member        Shelby Melton, MD
Member        Jill Murrell, PhD
Member        George J. Netto, MD
Member        Nirali M. Patel, MD
Member (Ex officio – President-Elect)    Victoria M. Pratt, PhD
Member        David Viswanatha, MD
Member        Barbara Zehnbauer, PhD
Junior Member        Amy Lo, MD
Junior Member        Jason Rosenbaum, MD
International Affairs Committee Liaison    David E. Barton, PhD
AMP Rep. to FASEB Science Policy Committee (Ex Officio)    Betsy A. Bove, PhD

PURPOSE SUMMARY:
The AMP Professional Relations Committee (PRC) is the primary liaison between AMP and other organizations for public policy issues other than reimbursement, which is the purview of the Economic Affairs Committee. Major responsibilities of the Committee include:

1. Communicating and coordinating activities with the appropriate government offices, coalitions, trade associations, and patient and professional organizations to inform policy discussions that have an impact on the practice of molecular pathology;
2. Developing AMP positions on emerging issues affecting molecular pathology;
3. Interacting with a wide variety of entities, including other professional associations, Congress and U.S. Federal Agencies such as FDA, CDC, DHHS;
4. Advocating for policy changes in legislation and regulation that will advance the practice of molecular pathology.

The committee membership includes individuals employed in a variety of medical, scientific, institutional and commercial capacities.

2018 ACTIVITIES:
The PRC continues to monitor the activities of, and in some cases work with, federal agencies and panels such as FDA and CMS as well as policy committees such as the Roundtable on Genomics and Precision Health at the National Academies of Sciences, Engineering, and Medicine. After extensive discussion, the committee drafts AMP’s policy positions and comments to federal agencies and members of Congress. AMP’s government relations consultants, Jennifer Leib, Megan Anderson Brooks, and Lindsey Trischler of CRD Associates, keep the Committee informed of all policy and legislative activity, assist in drafting policy positions, provide advice...
regarding advocacy strategies, and guide AMP’s presence on Capitol Hill. Jennifer Leib, Megan Anderson Brooks, AMP Senior Director of Public Policy and Advocacy, Tara Burke, AMP Public Policy Fellow, Sarah Thibault-Sennett and when possible, Committee or other AMP members meet with congressional staff to educate them about issues relevant to molecular pathology, to offer AMP’s expertise, and to advocate for AMP members’ interests. (Note: As a 501c3 tax-exempt organization, AMP is prohibited from participating in any partisan activities and may not have a Political Action Committee (PAC). In addition, its direct and grassroots lobbying activities are limited per IRC 501h.)

Oversight of Laboratory Developed Testing Procedures (LDPs)
A major advocacy issue of 2018 continued to be regulatory oversight of laboratory developed testing procedures (LDPs), also known as laboratory developed tests (LDTs). Since FDA announced their decision not to finalize their draft guidance for LDPs, conversations about LDP oversight have shifted to Congress. AMP remains actively engaged with legislators on Capitol Hill. AMP maintains that updating the Clinical Laboratory Improvement Amendments (CLIA) oversight will preserve a flexible system that fosters innovation and is also the most streamlined, cost-effective approach to addressing clinical and analytic validity and establishing enhanced transparency.

LDP advocacy efforts in 2018 involved communicating concern about a draft bill, released by Reps. Bucshon and DeGette in 2017, entitled “Diagnostic Accuracy and Innovation Act (DAIA).” DAIA proposes a single regulatory pathway oversight for both IVDs and LDPs under an entirely new center at FDA. While AMP provided detailed comments to the hill on this draft bill in 2017, there was increasing concern from AMP and other aligned stakeholders that hill conversations related to LDP oversight did not involve all relevant groups. To address this concern, AMP led a sign-on letter effort. The letter was signed by over 15 major organizations, laboratories, and academic medical centers stakeholders and was sent to relevant staffers on the House Committee on Energy and Commerce and the Senate Committee on Health, Education, Labor and Pensions. The letter expressed concerns regarding the draft legislation, the lack of stakeholder input during the development process, and states that updates to LDP oversight should be made primarily through updates to CLIA. Following the delivery of this letter, AMP and the stakeholders who signed the letter held multiple Hill meetings with members of the House E&C committee to disseminate and discuss the concerns expressed within the letter.

In August, the FDA released a technical assessment (TA) of the DAIA draft legislation that consisted of an alternative regulatory framework that differed substantially from that proposed in DAIA. AMP submitted comments expressing concerns and seeking clarification on a number of provisions within the TA. AMP also participated in a closed-door stakeholder meeting where FDA explained the regulatory proposal within their TA and answered questions.

Patient Advocacy Group Engagement
Since 2016, AMP has held “Lunch and Learn” events with patient groups, with the objective of identifying and establishing relationships with relevant patient groups in oncology, inherited conditions, and infectious diseases. AMP aims to understand the goals and needs of the patient groups, identify ways we can work together, and effectively communicate that patient care is central to AMP members’ practice. The events have been incredibly well-received with both the representatives from patient groups and AMP members excited by the things that were discussed.

In March, AMP held a Washington, D.C.-based lunch and learn hosted by Drs. Jordan Laser and Vicky Pratt with a focus on the current molecular diagnostic policy landscape. The next lunch and learn will take place at the Annual Meeting and a third event in Washington, D.C. is in the works for later in 2018 to discuss coverage and reimbursement issues affecting molecular diagnostics. The goals of these events are for the patient groups to gain a better understanding of why molecular pathology needs to be better incorporated into standard of care, the hurdles to achieving that, and how they can partner with AMP to make this a reality. Additionally, AMP is able to identify ways that they can engage and strengthen working relationships with the patient community in
In order to create the bidirectional conversation that will result in professional practice that reflects patients’ needs. The PRC is continuing these efforts and plans to continue this program in 2019.

**National Coverage Determination for NGS for Advanced Cancer for Medicare Beneficiaries**
The PRC assisted the Economic Affairs Committee (EAC) in developing comments to CMS on the National Coverage Determination for NGS for Advanced Cancer for Medicare Beneficiaries. The proposed coverage determination required FDA approval for national coverage of next generation sequencing oncology services and thus had serious implications not only for Medicare coverage but also oversight of these types of LDPs. The final policy released by CMS in March was significantly different than the proposed policy. Coverage for NGS-based tests were expanded to include FDA cleared and approved tests, rather than only FDA approved, with a companion diagnostic indication. A new section was added that allows Medicare Administrative Contractors (MACs) to determine coverage of other NGS-based tests for cancer when the test is performed in a CLIA-certified laboratory.

**Clinical Laboratory Improvement Amendments**
In March, AMP responded to a request for information from CMS regarding revisions to personnel regulations, proficiency testing referral, histocompatibility regulations and fee regulations under the CLIA. In addition to providing specific feedback on each section of the RFI, AMP commended CMS on their efforts to explore updating CLIA to better reflect current knowledge, changes in the academic context, and advancements in laboratory testing.

**Investigational IVDs used in Clinical Investigations of Therapeutic Products**
AMP provided comments to FDA on a draft guidance for investigational IVDs used in clinical investigations of therapeutic products. AMP appreciates the goal of FDA to provide stakeholders, including institutional review boards (IRBs), with more information in making determinations as to whether an IVD is investigational. However within the letter, AMP expressed concern that the guidance document provided unclear information regarding when molecular laboratory tests are subject to the FDA’s Investigational Device Exemption (IDE). In AMP’s letter, recommendations were provided to aid in refining the guidance document to assist clinical investigators working to improve patient care.

**Capitol Hill**
AMP continues to nurture existing and grow new relationships on Capitol Hill. Throughout 2018, AMP met with over 35 offices on Capitol Hill regarding oversight and regulation of LDPs. Specifically, AMP met with staff for Senate HELP and the offices of 13 other Senators. AMP also met with staff working for the House Energy and Commerce Committee and the House Ways and Means Committee, in addition to the offices of 15 Representatives.

**Collaborations**
AMP continues to participate in a variety of policy discussions with other professional societies, laboratory groups, as well as coalition groups such as the Personalized Medicine Coalition (AMP representatives Drs. Shelby Melton, Roger Klein, and Amy Lo), National Academies of Sciences, Engineering, and Medicine Roundtable on Genomics and Precision Health (AMP representative Dr. Vicky Pratt), Federation of American Societies for Experimental Biology (FASEB) (AMP representative Dr. Betsy Bove), and the Cancer Leadership Council.
COMMITTEE MEMBERS:
Chair Lynne V. Abruzzo, MD, PhD
Chair-Elect Neal Lindeman, MD
Genetics Representative Linda Jo Bone Jeng, MD, PhD
Genetics Representative Elaine B. Spector, PhD
Hematopathlogy Representative Eric J. Duncavage, MD
Hematopathlogy Representative Y. Lynn Wang, MD, PhD
Infectious Diseases Representative Belinda Yen-Lieberman, PhD
Infectious Diseases Representative Jennifer Dien Bard, PhD
Infective Diseases Representative Somak Roy, MD
Informatics Representative Matthew Lebo, PhD
Solid Tumors Representative Lynette Marie Sholl, MD
Solid Tumors Representative Christina Lockwood, PhD
Technical Topics Representative Lynne Whetsell, BS
Technical Topics Representative Fernanda Sabato, MS

PURPOSE SUMMARY:
The Program Committee is responsible for overall planning and organization of the AMP Annual Meeting, including sessions and abstracts/posters. In addition, the Committee selects the winners of the Technologist Poster Awards.

2018 ACTIVITIES:
Programming the 2018 Annual Meeting Expo, “Precision Medicine Starts Here” from November 1-3, 2018 at the Henry B. Gonzalez Convention Center in San Antonio, TX.
COMMITTEE MEMBERS:

Chair
JMD Editor-in-Chief
Test Directory Editor
Test Directory Co-Editor
Web Editor
Member
Member
Member
JMD Managing Editor
JMD Scientific Editor

Paul G. Rothberg, PhD
Barbara A. Zehnbauer, PhD
Alexis Carter, MD
Nefize Sertac Kip, MD PhD
Annette Leon Meredith, PhD
Mary C. Lowery-Nordberg, PhD
Dahui Qin, MD, PhD
Mohamadou Sene, BS, MB(ASCP)
Shalini Verma, MD
Shaochun Bai, PhD
Emily Essex
Chhavi Chauhan, PhD

PURPOSE SUMMARY: The Publication and Communication Committee is comprised of appointed volunteers from the AMP membership. The task of the Committee is to review and monitor all AMP “publications,” whether print or electronic. The committee communicates via monthly conference calls.

2018 ACTIVITIES:

• Solicited and reviewed submissions for the AMP/CAP TODAY Case Report Program
• Supported kickoff of AMP’s redesigned “AMPlifications” monthly newsletter
• Continued support and feedback for Test Directory Editors and Journal of Molecular Diagnostics editorial team
• Discussed compliance efforts for new General Data Protection Regulation (GDPR) in Europe
• Identified representative for FASEB Bio Advances Editorial Board
COMMITTEE MEMBERS:
Chair                  Victoria M. Pratt, PhD
Member                Michael Hadjisavas, PhD
Member                Annette S. Kim, MD, PhD
Member                Roger D. Klein, MD, JD
Member                Ester Stein, BS, MBA
Member                Karl V. Voelkerding, MD
President             Kojo S. J. Elenitoba-Johnson, MD
Executive Director    Mary Steele Williams, MNA, MT(ASCP)SM, CAE

PURPOSE SUMMARY:
The Strategic Opportunities Committee assesses the opportunities and challenges in the molecular pathology profession and other environments external to the organization that affect AMP interests.

2018 ACTIVITIES:
The Strategic Opportunities Committee carries out the activities listed below and provides relevant reports and recommendations to the Board of Directors:

• Assessing trends and activities in the broad environment external to AMP, i.e., "Horizon Scanning"
• Identifying and assessing external threats that could prevent AMP from attaining its goals
• Identifying and assessing external opportunities that can help AMP attain its goals
• Identifying organizations for potential relationships that can help AMP attain its goals
COMMITEE MEMBERS:

Chair                          Cecilia C. S. Yeung, MD
Genetics Subdivision Representative    Kristy R. Crooks, PhD
Genetics Subdivision Representative    Yassmine Akkari, PhD
Hematopathology Subdivision Representative    Mark D. Ewalt, MD
Hematopathology Subdivision Representative    Rashmi S. Goswami, MD, PhD
Infectious Diseases Subdivision Representative    Sophie S. Arbefeville, MD
Infectious Diseases Subdivision Representative    Preeti Pancholi, PhD
Informatics Subdivision Representative    Joshua F. Coleman, MD
Informatics Subdivision Representative    Sabah Kadri, PhD
Solid Tumors Subdivision Representative    Anna Yemelyanova, MD
Solid Tumors Subdivision Representative    Susan J. Hsiao, MD
Junior Member                        Jeffrey Gagan, MD, PhD
Junior Member                        Brittany Coffman, MD
Medical Technologist Member           Barbara Anderson, BS, MS
Medical Technologist Member           Mara Williams, MS
Membership Affairs Committee Liaison    Cynthia Jackson, PhD
International Affairs Committee Liaison    Roberta Sitnik, PhD

PURPOSE SUMMARY:
The Training and Education (T&E) Committee is comprised of representatives from each of AMP’s subdivisions: genetics, hematopathology, infectious diseases, informatics and solid tumors as well as technologist representatives, junior members, and liaisons from the International Affairs and Membership Affairs Committees (IAC and MAC). It oversees important issues such as education and certification in molecular pathology and mentoring of trainees, as well as developing educational programs for different audiences.

Educational Programs

- **Molecular Pathology Outreach Course (MPOC 2018):** The T&E Committee organized an annual outreach course held just prior to annual meeting on October 31, 2018, which was geared to individuals with little experience in molecular diagnostics. This year the course was entitled “AMPlicons: A Practical Molecular Toolkit and Case Studies.” The course included an overview of pre-analytic considerations in molecular pathology, followed by case studies presented by T&E members that illustrated a wide range of molecular diagnostic applications.

- **Early Bird Sessions at the Annual Meeting & Expo - Case Studies presented by Trainees or Technologists:** The T&E Committee hosted an opportunity for fellows, residents, postdocs, graduate students, or technologists who attended the AMP 2018 Annual Meeting & Expo to present an interesting and/or challenging case study during an Early Bird Session. Trainee/technologist presenters in 2018 were:
<table>
<thead>
<tr>
<th>Case Studies in Genetics and Informatics</th>
<th>Case Study: Utilization of Mate-Pair Sequencing to Aid in the Diagnosis of a Patient with a De Novo Balanced Translocation</th>
<th>Nicole Boczek, PhD</th>
<th>Mayo Clinic, Rochester, MN</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Case Study: Identification of a Novel Likely Pathogenic PIK3R1 Variant by Targeted Next-generation Sequencing Analysis in a Patient with Overgrowth Syndrome and Lymphatic Malformation</td>
<td>Christopher Suciu, MD, MS</td>
<td>Washington University School of Medicine, St. Louis, MO</td>
</tr>
<tr>
<td></td>
<td>Case Study: Sex Check: Verifying Patient Sex Based on Off-panel SNPs on the X Chromosome</td>
<td>Jennifer Bynum, MD</td>
<td>Johns Hopkins University, Baltimore, MD</td>
</tr>
<tr>
<td></td>
<td>Case Study: A Discrepancy Between the Human Reference Genome (GRCh37) and Transcriptome (RefSeq) Results in the Incorrect Annotation of a Clinically-relevant Sequence Variant in RECQL4</td>
<td>Lisa Lansdon, PhD</td>
<td>Children’s Mercy Hospital, Kansas City, MO</td>
</tr>
<tr>
<td>Case Studies in Solid Tumors</td>
<td>Case Study: Circulating Tumor DNA (ctDNA) Detection in CSF in a Patient with Metastatic Melanoma to the CNS</td>
<td>Andres Moon, MD</td>
<td>University of Washington, Seattle, WA</td>
</tr>
<tr>
<td></td>
<td>Case Study: An Unusual Driver Mutation in a Lung Adenocarcinoma</td>
<td>Erik Nohr, MD</td>
<td>Stanford Healthcare, Palo Alto, CA</td>
</tr>
<tr>
<td></td>
<td>Case Study: LMNA/NTRK1 Fusion in a Paravertebral Soft Tissue Mass</td>
<td>Yulei Shen, MD, PhD</td>
<td>Baylor College of Medicine, Houston, TX</td>
</tr>
<tr>
<td></td>
<td>Case Study: Recurrent Glioblastoma with Primary and Secondary Features in a Patient with a Deficiency of Mismatch Repair</td>
<td>Martin Powers, MD</td>
<td>University of California, San Diego CA</td>
</tr>
<tr>
<td>Case Studies in Hematopathology</td>
<td>Case Study: Identification of a rare germline POT1 mutation by targeted next-generation sequencing of a splenic marginal zone lymphoma</td>
<td>Audrey Jajosky, MD, PhD</td>
<td>University Hospitals Cleveland Medical Center, Cleveland, OH</td>
</tr>
<tr>
<td></td>
<td>Case Study: Identification of Acute Leukemia Risk Mutations in a Child with Severe Congenital Neutropenia</td>
<td>Jennifer Yoest, MD</td>
<td>Washington University School of Medicine, St. Louis, MO</td>
</tr>
<tr>
<td></td>
<td>Case Study: Whole Genome Sequencing Identifies Cryptic High-risk Cytogenetic Findings in a Patient with Acute Myeloid Leukemia</td>
<td>Michael Alberti, MD, PhD</td>
<td>Washington University School of Medicine, St. Louis, MO</td>
</tr>
<tr>
<td></td>
<td>Case Study: A Case of Myeloid Neoplasm with Germline Predisposition: Connecting the Clinical, Laboratory, Morphology and Molecular Dots</td>
<td>Fatima Z. Jelloul, MD</td>
<td>MD Anderson Cancer Center, Houston, TX</td>
</tr>
</tbody>
</table>
### Webcasts and Recorded Online Content (ROCs):

<table>
<thead>
<tr>
<th>Date</th>
<th>Major Initiative / Topic</th>
<th>Title</th>
<th>Speaker/T&amp;E Moderator</th>
<th>NOTES</th>
</tr>
</thead>
<tbody>
<tr>
<td>May 29</td>
<td>Major Initiative: Advancing Patient Care in NSCLC: Breaking Down Barriers</td>
<td><strong>NSCLC Guidelines:</strong> Molecular Testing Guideline for Selection of Lung Cancer Patients - Revision</td>
<td>Neal Lindeman / Anna Yemelyanova</td>
<td></td>
</tr>
<tr>
<td>June 20</td>
<td>Major Initiative: Advancing Patient Care in NSCLC: Breaking Down Barriers</td>
<td><strong>NSCLC Guidelines:</strong> Best Practices in NSCLC Small Specimen Collection for Clinicians</td>
<td>Eric Bemickier / Christopher Gilbert</td>
<td></td>
</tr>
<tr>
<td>October 9</td>
<td>Major Initiative: Advancing Patient Care in NSCLC: Breaking Down Barriers</td>
<td><strong>NSCLC Guidelines:</strong> Liquid Biopsies - Promises and Pitfalls</td>
<td>Lynette Sholl / Christina Lockwood</td>
<td></td>
</tr>
<tr>
<td>December 13</td>
<td>Major Initiative: Advancing Patient Care in NSCLC: Breaking Down Barriers</td>
<td><strong>NSCLC Guidelines:</strong> Best Practices in Test Ordering</td>
<td>Sinchita Roy-Chowdhuri and Christopher R. Gilbert</td>
<td></td>
</tr>
<tr>
<td>June 27</td>
<td>Major Initiative: Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care</td>
<td><strong>Tumor Mutational Burden:</strong> Clinical and Diagnostic Utilization in Oncology</td>
<td>Lauren Ritterhouse / Susan Hsiao</td>
<td></td>
</tr>
<tr>
<td>August 28</td>
<td>Major Initiative: Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care</td>
<td><strong>Tumor Mutational Burden:</strong> Best Practices to Address Clinical and Technical Challenges</td>
<td>Jonathan Nowak / Jeremy Segal</td>
<td></td>
</tr>
<tr>
<td>September 26</td>
<td>Major Initiative: Tumor Mutational Burden: Challenges and Opportunities for Improving Cancer Patient Care</td>
<td><strong>Tumor Mutational Burden:</strong> Result Reporting and Application to Improve Patient Care</td>
<td>Ahmet Zehir / Jonathan Nowak</td>
<td></td>
</tr>
<tr>
<td>January 22</td>
<td>Webinar Series: 2016 World Health Organization (WHO) Updates in Hematologic Malignancies</td>
<td><strong>WHO Revisions:</strong> Update on the 2016 WHO Classification of Acute Leukemias</td>
<td>Dan Arber / Mark Ewalt</td>
<td>ROC: WHO Guideline Series</td>
</tr>
<tr>
<td>February 2</td>
<td>Webinar Series: 2016 World Health Organization (WHO) Updates in Hematologic Malignancies</td>
<td><strong>WHO Revisions:</strong> B-Lymphoid Neoplasms (and how practice is changing)</td>
<td>Eric Hsi / Mark Ewalt</td>
<td>ROC: WHO Guideline Series</td>
</tr>
<tr>
<td>March 1</td>
<td>Webinar Series: 2016 World Health Organization (WHO) Updates in Hematologic Malignancies</td>
<td><strong>WHO Revisions:</strong> Myeloproliferative Neoplasms</td>
<td>Tracy George / Mark Ewalt</td>
<td>ROC: WHO Guideline Series</td>
</tr>
<tr>
<td>January 26</td>
<td>Webinar Series: 2016 World Health Organization (WHO) Updates in Hematologic Malignancies</td>
<td>AMP/ASCO/CAP Standards and Guidelines of Somatic Variant Interpretation and Reporting</td>
<td>Marilyn Li / Antonia Sepulveda</td>
<td>ROC: CPC Guideline</td>
</tr>
<tr>
<td>April 25</td>
<td>Webinar Series: 2016 World Health Organization (WHO) Updates in Hematologic Malignancies</td>
<td>Practical Considerations for the Validation of Next-Generation Sequencing-Based Oncology Panels</td>
<td>Lary Jennings / Antonia Sepulveda</td>
<td>CPC Guideline</td>
</tr>
<tr>
<td>July 17</td>
<td>Webinar Series: 2016 World Health Organization (WHO) Updates in Hematologic Malignancies</td>
<td>Global ROCs: Complexities in the Analysis and Interpretation of NGS Data for Inherited Disorders</td>
<td>Avni Santani / Kristy Crooks</td>
<td>CPC Guideline</td>
</tr>
<tr>
<td>July 19</td>
<td>Webinar Series: 2016 World Health Organization (WHO) Updates in Hematologic Malignancies</td>
<td>Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms (CMNs)</td>
<td>Annette Kim / Todd Kelley</td>
<td>CPC Guideline</td>
</tr>
<tr>
<td>September 18</td>
<td>Webinar Series: 2016 World Health Organization (WHO) Updates in Hematologic Malignancies</td>
<td>The ABCs of CPT® Coding</td>
<td>Aaron Bossler, Vicky Prat and Anthony Sireci / Cecilia Yeung</td>
<td>EAC Collaboration</td>
</tr>
<tr>
<td>ROC</td>
<td>Lab Management Series: Feel like QC and IQCP are affecting your IQ?</td>
<td>Lab Management Series: Feel like QC and IQCP are affecting your IQ?</td>
<td>Ana Maria Cardenas</td>
<td></td>
</tr>
<tr>
<td>ROC</td>
<td>Lab Management Series: Reporting Results of Molecular Pathology Laboratory Tests</td>
<td>Lab Management Series: Reporting Results of Molecular Pathology Laboratory Tests</td>
<td>Peggy Gulley</td>
<td></td>
</tr>
<tr>
<td>ROC</td>
<td>Lab Management Series: Scientific Aspects of Test Development in the Molecular Pathology Lab</td>
<td>Lab Management Series: Scientific Aspects of Test Development in the Molecular Pathology Lab</td>
<td>Peggy Gulley</td>
<td></td>
</tr>
</tbody>
</table>
Education Initiatives

- **Continuing Education credits (SAMs, CME, and CMLE):** AMP offers Continuing Education credits for many of its educational activities. Accredited activities include the MGP Review Course (live and online), the MPOC, the 2018 Annual Meeting & Expo, and Recorded Online Content (ROC) lectures.

- **AMP Online:** The T&E Committee and staff spent significant time designing and developing educational materials for populating the online learning platform at educate.amp.org. Selected online educational offerings are complimentary for AMP members. Current content includes a 3-webinar series on Tumor Mutational Burden, a 5-webinar series on NSCLC, the online MGP Review Course, the Molecular Diagnostic Toolkit and Practical Applications, 2017 Annual Meeting highlights, Global Congress highlights, and AMP Europe 2018 Highlights.

- **Target Audience Groups (TAGs):** The T&E committee established TAGs within the T&E Committee dedicated to the development of new educational materials to extend the positive influence and educational mission of AMP to meet the needs of molecular professionals and non-molecular audiences. The following TAGs were created: Trainees, Technologists, Oncologists, Primary Care Physicians, and the lay (non-medical) public.

- **Pocket Cards:** The T&E Committee designed “Molecular in my Pocket” reference cards with topics from the Infectious Diseases, Hematopathology, Solid Tumors, and Genetics subdivisions. These cards were created to target trainees and, more recently, oncologists/clinician audiences were targeted with oncology pocket cards on Myeloproliferative Neoplasms, Molecular Biomarkers of Colorectal Cancer, Molecular Biomarkers of Thyroid Cancer, and Interpretation of Genomic Assays. These are available online, but hard copies are also distributed at the MGP Review Course, the USCAP annual meeting, and AMP Central.

- **FISE Question Bank:** Done in collaboration with the MGP-PD Council, the exam questions were written by MGP faculty from many MGP-Fellowship institutions and cover a range of topics. The T&E Committee screens all questions. For each examination, a total of 45 questions randomly populated from a question bank of approximately 200 questions is given, yielding a different test each time. AMP staff provides non-attributed results to participating institutions at the beginning of the fellowship year (in October) and at the end of the year (in May/June).

- **Course Bundles/AMP Certificate Programs:**
  - **WHO updates:** A content series on the WHO guidelines using existing LMS content augmented with materials dictated by content-directors Jennifer Dunlap and Mark Ewalt.
  - **Course bundles:**
    - Circulating tumor DNA testing – advances, challenges, and applications
    - Infectious Disease: From Emerging Pathogens to Emerging Paradigms
    - Laboratory Management Online Curriculum

Trainee Activities (Residents, Fellows, and Students)

- **AMP 2018 Annual Meeting & Expo**
  - Trainee and Technologists Luncheon and Book Drawing: The T&E junior and technologist members organized table discussion topics between junior and senior faculty members at the 2018 Training & Education Luncheon. Donated textbooks from AMP member authors were given away during the Trainee Luncheon.
Technologist Activities
• Technologist Career presentation at the Annual Meeting’s Innovation Stage
• Technologist mixer at AMP Central during the Annual Meeting
• Ongoing planning of the development and coordination of resources for technologists

Awards
• Young Investigator Awards – 35 poster candidates
• Technologist Poster Awards – 20 poster candidates
• International Trainee Travel Award (Supported by the Jeffrey A. Kant – AMP Education Fund) – Three recipients (from Brazil, Germany and India).

Molecular Genetic Pathology Fellowship Program Directors (MGP PD) Working Group
The MGP Program Directors (MGP PD) Council consists of Shuko Harada (Chair), Allison Cushman-Vokoun (Chair-Elect), and Dolores Lopez-Terrada (Past-Chair). The MGP PD Council facilitates the discussions of the MGP Program Directors Working Group and responds to the ABP and ACGME on matters related to MGP Fellowship programs. The Council worked with the T&E Committee to launch an in-service practice exam question bank for MGP Fellows.

Curriculum Development Task Forces

• Genomics Education for Primary Care Residents: This Task Force is led by Laura Tafe. Their task is to develop a modified basic genomics curriculum for primary care residents, i.e., internal medicine, family practice, pediatrics to be submitted to a primary care-type journal. Other working group members are Yassmine Akkari, Maria Arcila, Devon Chabot-Richards and Anthony Snow.

• MGP Fellow Training and Curriculum in Genomics Task Force: The Task Force is headed by co-leaders Jason Rosenbaum and Mark Ewalt and includes working group members Kristy Crooks, Jeff Gagan and David Wu. The manuscript is in the final stages of outlining a suggested molecular pathology and genomics curriculum for fellows. Upon completion, the manuscript will be submitted to JMD. Additional authors are: Anna Berry, Alanna Church, Linda Jeng, Roger Klein, Mahesh Mansukhani, Federico Monzon, John Pfeifer, Hanna Rennert, Iris Schrijver, Laura Tafe, Vivianna Van Deerlin and David Wu.

Co-Sponsorships, Companion Meetings, and/or Collaborations

• Joint AMP – Society for Hematopathology Webinar Series on the 2016 WHO Updates in Molecular Testing
• United States and Canadian Academy of Pathology (USCAP) 2018
The AMP 2018 Companion Society Symposium, “Lessons Learned in Molecular Pathology”, was co-moderated by Cecilia Yeung and Yaolin Zhou:
  o Image Analysis and Biomarker Evaluation: Linking Digital Pathology, Andrew Evans, MD, PhD
  o High-Throughput Cancer Genomics as a Disruptive Technology, Fei Dong, MD
  o Synergism Between Liquid Biopsy Testing and Pathology, Christina Lockwood, PhD

An AMP Short Course, AMPlicons: Basic Tools and Emerging Fronts in Molecular was co-presented by Annette Kim, MD, PhD and Cecilia Yeung, MD.

An AMP-USCAP co-sponsored Special Course, Molecular Diagnostic and Genomic Applications in Cancer: A Primer for the Pathologist, was co-directed by George Netto, MD, and Karen Kaul, MD, PhD
• **American Society for Clinical Pathology (ASCP)**  
  o ASP 2018 AMP Workshop: October 2-5 in Baltimore, MD: Molecular Diagnostics Primer- Basic Principles and Molecular Diagnostics Primer- Advanced Topics were presented by Mark Ewalt and Jason Rosenbaum.

• **College of American Pathologists (CAP)**  
  o CAP 2018 Course Presentations: October 20-24 in Chicago, IL  
    ➢ The WHO and Beyond: The Myeloproliferative Neoplasms was presented by Mark Ewalt and Cecilia Yeung.  
    ➢ CAP-IASLC-AMP Molecular Testing Guidelines for Selection of Lung Cancer Patients—Revision was presented by Neal Lindeman

• **Regional/Local Conferences**  
  o Beaumont Symposium: September 13-14 in Troy, MI.  
    Organizer: Bobby Boyanton.

• **Cambridge Health Institute (CHI) Conferences**  
  o Molecular Medicine Tri-Conference, February 11-16, 2018, San Francisco, CA  
    ▪ Short Courses:  
      ▪ **NGS Assay Selection, Validation and Compliance**: Maria E. Arcila, Eric Duncavage, Birgit Funke.  
      ▪ **Clinical Informatics: Returning Results from Big Data**: N. Sertac Kip, Mark Routbort, and Stephen E. Lincoln  
    ▪ Keynote Session  
      ▪ **New Clinical Practice Guidelines for NGS-Guided Oncology**: Maria E. Arcila, Somak Roy, and Marina N. Nikiforova.
  o Next Generation Dx Summit, August 20-24, 2018, Washington, DC  
    ▪ Plenary Keynote Session Panel: Global Dx Insights: Policy and Prediction for Diagnostics: Vicki Pratt, panelist  
    ▪ AMP Co-organized Plenary Session: Technology Panel: Disruptive Technologies in Lab Medicine Moderator: Gregory J. Tsongalis  
  o Biomarkers & Immuno-Oncology World Congress, June 11-13, 2018 | Boston, MA  
    ▪ **Precision Oncology: Practical Strategies for Genomic Test Implementation with Case Vignettes**: Christina Lockwood

• **ASCO-CAP-AMP Molecular Oncology Tumor Boards**  
  The Molecular Oncology Tumor Boards are a series of monthly user-driven discussions designed to help cancer care providers with the interpretation and understanding of tumor molecular profiling tests and studies: [http://university.asco.org/motb](http://university.asco.org/motb). AMP collaborates with the American Society for Clinical Oncology (ASCO) and the College of American Pathologists (CAP).  
  o AMP Representatives: Maria Arcila and Christopher Watt.
SUBDIVISION LEADERSHIP

<table>
<thead>
<tr>
<th>SUBDIVISION</th>
<th>Genetics</th>
<th>Hematopathology</th>
<th>Infectious Diseases</th>
<th>Informatics</th>
<th>Solid Tumors</th>
</tr>
</thead>
<tbody>
<tr>
<td>Chair</td>
<td>Birgit Funke</td>
<td>Annette Kim</td>
<td>David Hillyard</td>
<td>Alexis Carter</td>
<td>Roger Klein</td>
</tr>
<tr>
<td>Clinical Practice Committee</td>
<td>Jess Peterson</td>
<td>Keyur Patel</td>
<td>Susan Butler-Wu</td>
<td>Mark Boguski</td>
<td>Kandelaria Rumilla</td>
</tr>
<tr>
<td></td>
<td>Joshua Deignan</td>
<td>Noah Brown</td>
<td>Kenneth Muldrew</td>
<td>Justin Zook</td>
<td>Pranil Chandra</td>
</tr>
<tr>
<td>Nominating Committee</td>
<td>Carolyn Sue Richards</td>
<td>Rachel Sargent</td>
<td>James Dunn</td>
<td>Brian Shirts</td>
<td>John Thorson</td>
</tr>
<tr>
<td></td>
<td>Bert Gold</td>
<td>David Viswanatha</td>
<td>Amanda Harrington</td>
<td>Carlos Jose Suarez</td>
<td>Shelby Melton</td>
</tr>
<tr>
<td>Program Committee</td>
<td>Linda Jo Bone Jeng</td>
<td>Eric Duncavage</td>
<td>Belinda Yen-Lieberman</td>
<td>Somak Roy</td>
<td>Lynette Sholl</td>
</tr>
<tr>
<td></td>
<td>Elaine Spector</td>
<td>Lynn Wang</td>
<td>Jennifer Dien Bard</td>
<td>Matthew Lebo</td>
<td>Christina Lockwood</td>
</tr>
<tr>
<td>Training &amp; Education Committee</td>
<td>Kristy Crooks</td>
<td>Mark Ewalt</td>
<td>Sophie Arbefeville</td>
<td>Joshua Coleman</td>
<td>Anna Yemelyanova</td>
</tr>
<tr>
<td></td>
<td>Yassmine Akkari</td>
<td>Rashmi Goswami</td>
<td>Preeti Pancholi</td>
<td>Sabah Kadri</td>
<td>Susan Hsiao</td>
</tr>
</tbody>
</table>

PURPOSE SUMMARY:
The Subdivision Leadership consists of a Chair and Representatives to the Clinical Practice, Nominating, Program, and Training & Education Committees. Subdivision Chairs are responsible for the successful operation and development of the subdivision that they lead.

Each Subdivision Leadership group meets quarterly and functions in an AMP advisory panel of discipline-specific subject matter experts convened to address issues of importance to their Subdivision. They carry out their subdivision leadership responsibilities by:

- Identifying and ascertaining the needs of the Subdivision membership and of the discipline itself
- Discovering, vetting, and recommending projects to the Clinical Practice Committee, Training and Education Committee, or other relevant committee
- Providing input and suggestions regarding content for the Annual Meeting and other educational events
- Assisting to identify and recommend future AMP volunteers and leaders

2018 ACTIVITIES

**Genetics** - Addressed contemporary genetics topics as they relate to the clinical molecular diagnostics laboratory, including variant interpretation, variant confirmation methods and newborn genomic sequencing.

**Hematopathology** - Addressed topics in molecular hematopathology, including advances in translational research related to genomics and mutations in hematologic malignancies, resistance to targeted therapies, next-generation sequencing and immunology.

**Infectious Diseases**
Addressed infectious disease topics relevant to the clinical molecular diagnostics laboratory, including next-generation sequencing, microbiome, immunotherapy and emerging molecular infectious disease testing platforms. Hosted additional special sessions on meningitis/encephalitis syndromic testing and genomic
susceptibility testing. Developed and hosted ID Town Hall at the AMP 2018 Annual Meeting to engage AMP ID Subdivision members regarding challenges and opportunities for the infectious diseases community and explore how AMP might best address them.

**Informatics** - Addressed topics related to clinical applications and development of validation guidelines for next-generation sequencing bioinformatics pipelines for somatic variants and other developments in clinical molecular informatics pertaining to the use of artificial intelligence.

**Solid Tumors** - Addressed topics related to clinical applications and development of next-generation sequencing validation guidelines for somatic variants, genomic tumor diversity, liquid biopsies and other evidence-based clinical practice guidelines projects.

Subdivision members provided invaluable assistance to the Economic Affairs Committee on drafting comments to proposed LCDs for molecular pathology procedures and genomic sequence analysis panels in the treatment of hematolymphoid diseases. The responses were submitted jointly with the College of American Pathologists (CAP). The ID Subdivision members also assisted with providing recommendations to CMS for new and reconsidered CPT codes pertaining to infectious diseases.

Members of the Subdivision Leadership participated in the “Get involved with AMP” event at the Annual Meeting to engage with their respective Subdivision members and inform them of AMP’s initiatives and projects in their interest areas.

**Requests from the Subdivision Leadership**

- We encourage all AMP members to alert their Subdivision Chair or Representatives for current or emerging specific needs that AMP should consider and address.
- We encourage AMP members to actively contribute to requests for information from their respective Subdivision Leadership.